0000899243-18-028967.txt : 20181114
0000899243-18-028967.hdr.sgml : 20181114
20181114210052
ACCESSION NUMBER: 0000899243-18-028967
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181112
FILED AS OF DATE: 20181114
DATE AS OF CHANGE: 20181114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ginn Scott G
CENTRAL INDEX KEY: 0001543701
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24260
FILM NUMBER: 181185802
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMEDISYS INC
CENTRAL INDEX KEY: 0000896262
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082]
IRS NUMBER: 113131700
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
BUSINESS PHONE: 2252922031
MAIL ADDRESS:
STREET 1: 3854 AMERICAN WAY
STREET 2: SUITE A
CITY: BATON ROUGE
STATE: LA
ZIP: 70816
FORMER COMPANY:
FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP
DATE OF NAME CHANGE: 19940819
FORMER COMPANY:
FORMER CONFORMED NAME: M&N CAPITAL CORP
DATE OF NAME CHANGE: 19930125
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-12
0
0000896262
AMEDISYS INC
AMED
0001543701
Ginn Scott G
3854 AMERICAN WAY, SUITE A
BATON ROUGE
LA
70816
0
1
0
0
Chief Financial Officer
Common Stock
2018-11-12
4
M
0
1875
27.35
A
16664
D
Common Stock
2018-11-12
4
M
0
3750
27.35
A
20414
D
Common Stock
2018-11-12
4
S
0
800
115.97
D
19614
D
Common Stock
2018-11-12
4
S
0
4095
117.10
D
15519
D
Common Stock
2018-11-12
4
S
0
1945
117.99
D
13574
D
Common Stock
2018-11-12
4
S
0
800
119.01
D
12774
D
Common Stock
2651
I
Through 401(k) Plan
Stock Option (right to buy)
27.35
2018-11-12
4
M
0
1875
0.00
D
2018-05-01
2025-05-01
Common Stock
1875
0
D
Stock Option (right to buy)
27.35
2018-11-12
4
M
0
3750
0.00
D
2025-05-01
Common Stock
3750
1875
D
The total amount of shares beneficially owned includes 887 shares held in an employee stock purchase plan account.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.46 to $116.40, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.49 to $118.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.49 to $119.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
The information in this report is based on a plan statement dated as of September 30, 2018.
On May 1, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2015 were met, resulting in vesting of the option as to 5,625 shares (the "2015 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2015 Tranche Options vested on May 1, 2016, one-third of the 2015 Tranche Options vested on May 1, 2017 and one-third of the 2015 Tranche Options vested on May 1, 2018.
On May 1, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2016 were met, resulting in vesting of the option as to 5,625 shares (the "2016 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2016 Tranche Options vested on May 1, 2017, one-third of the 2016 Tranche Options vested on May 1, 2018 and one-third of the 2016 Tranche Options will vest on May 1, 2019, provided that the reporting person remains continuously employed by the Issuer on such date, subject to pro-rated vesting provisions as provided in the award agreement for the stock option.
/s/ Jennifer R. Guckert, pursuant to a power of attorney
2018-11-14